Actively Recruiting
Study of Urinary Tubular Biomarkers to Improve Prediction of Chronic Kidney Disease Progression in Adults with Stage 3 CKD
Led by Erasmus Medical Center · Updated on 2025-08-07
556
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying chronic kidney disease CKD stage 3 to improve how the progression of this condition is predicted. CKD affects over 800 million people worldwide and is a leading cause of death. Current tests focus only on the kidneys filtering part, the glomerulus, but this study evaluates the kidneys tubule function, which plays a key role in disease progression and is targeted by new protective treatments. The goal is to develop a urine test panel that better predicts CKD progression to help start treatment earlier. This study uses a urinary tubular test panel applied to urine samples collected during routine outpatient care. The test includes measuring urine supersaturation and urinary extracellular vesicle biomarkers. The results will be compared with current standard measures but will not affect patient treatment, which continues as usual. No additional risks or burdens are expected since urine samples are collected as part of standard care. Participants will be adult patients with CKD stage 3. The study involves analyzing urine samples and comparing the new tests predictions with established kidney function tests. The main outcome is assessing CKD progression over three years. Participants will remain under standard outpatient treatment during the study, and written informed consent, including permission to store samples for future use, will be obtained. The study is observational and sponsored by Erasmus Medical Center.
CONDITIONS
Brief Title
Urinary Tubular Biomarkers for Chronic Kidney Disease
Research Team
S
Sebastian Beckmann, MD
M
Madonna Salib, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here